Aktis Oncology (NASDAQ:AKTS) Q3 2026 Results Miss Estimates as Costs Rise
Aktis: Q3 Earnings Snapshot
Aktis Oncology Reports Third-Quarter Financial Results and Highlights Clinical Trial Progress
Aktis Oncology Q3 EPS $(0.54) Misses $(0.48) Estimate, Sales $3.905M Miss $4.016M Estimate
Does Aktis (AKTS) Have the Potential to Rally 105.62% as Wall Street Analysts Expect?
Aktis Oncology: Padcev Is Building The Market It Wants
Wedbush Reiterates Outperform on Aktis Oncology, Maintains $35 Price Target
Aktis Oncology Initiates Second Phase 1b Clinical Trial for AKY-2519, a Miniprotein Radioconjugate Targeting B7-H3
Aktis Oncology Initiates Second Phase 1b Clinical Trial for AKY-2519
Aktis Oncology, Inc. (AKTS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Aktis Oncology to Present at Upcoming September Investor Conferences
Oppenheimer Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $40
Aktis Oncology Seen Advancing Targeted Radiation-Based Cancer Drugs, Wedbush Says
Wedbush Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $35
BMO Capital Initiates Coverage On Aktis Oncology with Outperform Rating, Announces Price Target of $37
Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026
Aktis Oncology Q2 EPS $(0.44) Misses $(0.43) Estimate, Sales $3.384M Beat $2.000M Estimate
JP Morgan Maintains Overweight on Aktis Oncology, Raises Price Target to $33
Raymond James Initiates Coverage On Aktis Oncology with Strong Buy Rating, Announces Price Target of $40
Aktis Oncology, Inc. (AKTS) Presents at Jefferies Global Healthcare Conference 2026 - Slideshow
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.